Posted by Michael Wonder on 03 Oct 2023
Adalimumab-adbm, Boehringer Ingelheim’s Interchangeable biosimilar to Humira, now available at low wholesale acquisition cost
2 October 2023 - Adalimumab-adbm will be priced at an 81% discount to Humira (adalimumab).
Boehringer Ingelheim announced today that adalimumab-adbm injection, the company’s interchangeable biosimilar to Humira (adalimumab), is now available at a low wholesale acquisition cost.
